Polyomavirus-associated nephropathy

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 2, Issue 6

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

499

HTML

3665

Tables (1-4)

187

Sum=4351

Dec 24, 2012 (publication date) through Nov 18, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Transplantation

ISSN

2220-3230

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Transplant. Dec 24, 2012; 2(6): 84-94
Published online Dec 24, 2012. doi: 10.5500/wjt.v2.i6.84

Table 3 Algorythm for the virological monitoring of polyomavirus BK replication in renal transplantation[49]

Assay	Notes	Timing - intervention
Screening	Positive screening test (possible PVAN)	Every 3 mo up to 2 yr post-transplantation or in case of allograft dysfunction or when renal biopsy is performed
Urine cytology (decoy cells) or urine DNA load	Positive screening test (possible PVAN)
Adjunctive quantitative tests (threshold)	Presumptive PVAN	Pre-emptive reduction of immunosuppression
Urine DNA load > 10⁷ copies/mL or plasma DNA load > 10⁴ copies/mL		Pre-emptive reduction of immunosuppression
Allograft biopsy	Definitive diagnosis of PVAN
Monitoring of response to treatment		Every 2-4 wk
Urine DNA load decreasing or plasma DNA load decreasing		Every 2-4 wk
Serum creatinine
	Negative monitoring test (resolved PVAN)

PVAN: Polyomavirus-associated nephropathy.

Citation: Costa C, Cavallo R. Polyomavirus-associated nephropathy. World J Transplant 2012; 2(6): 84-94
URL: https://www.wjgnet.com/2220-3230/full/v2/i6/84.htm
DOI: https://dx.doi.org/10.5500/wjt.v2.i6.84